Literature DB >> 12666659

Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus.

Carmine Morisco, Junichi Sadoshima, Bruno Trimarco, Rohit Arora, Dorothy E Vatner, Stephen F Vatner.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12666659     DOI： 10.1152/ajpheart.00990.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN： 0363-6135            Impact factor:   4.733


× No keyword cloud information.
  14 in total

1.  SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway.

Authors:  Antonio Cittadini; Maria Gaia Monti; Guido Iaccarino; Maria Carmina Castiello; Alfonso Baldi; Eduardo Bossone; Salvatore Longobardi; Alberto Maria Marra; Valentina Petrillo; Lavinia Saldamarco; Matthew John During; Luigi Saccà; Gianluigi Condorelli
Journal:  Cardiovasc Res       Date:  2012-08-08       Impact factor: 10.787

2.  Calcium handling proteins: structure, function, and modulation by exercise.

Authors:  Jamille Locatelli; Leonardo V M de Assis; Mauro C Isoldi
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

3.  Endogenous muscle atrophy F-box mediates pressure overload-induced cardiac hypertrophy through regulation of nuclear factor-kappaB.

Authors:  Soichiro Usui; Yasuhiro Maejima; Jayashree Pain; Chull Hong; Jaeyeaon Cho; Ji Yeon Park; Daniela Zablocki; Bin Tian; David J Glass; Junichi Sadoshima
Journal:  Circ Res       Date:  2011-05-26       Impact factor: 17.367

4.  T-tubule remodeling during transition from hypertrophy to heart failure.

Authors:  Sheng Wei; Ang Guo; Biyi Chen; William Kutschke; Yu-Ping Xie; Kathy Zimmerman; Robert M Weiss; Mark E Anderson; Heping Cheng; Long-Sheng Song
Journal:  Circ Res       Date:  2010-06-24       Impact factor: 17.367

5.  In vivo key role of reactive oxygen species and NHE-1 activation in determining excessive cardiac hypertrophy.

Authors:  Oscar H Cingolani; Néstor G Pérez; Irene L Ennis; María C Alvarez; Susana M Mosca; Guillermo R Schinella; Eduardo M Escudero; Gloria Cónsole; Horacio E Cingolani
Journal:  Pflugers Arch       Date:  2011-08-26       Impact factor: 3.657

6.  Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors.

Authors:  Danyan Xu; Ning Li; Yuxia He; Valeriy Timofeyev; Ling Lu; Hsing-Ju Tsai; In-Hae Kim; Dipika Tuteja; Robertino Karlo P Mateo; Anil Singapuri; Benjamin B Davis; Reginald Low; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-27       Impact factor: 11.205

7.  Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload.

Authors:  Tetsuro Ago; Yanfei Yang; Peiyong Zhai; Junichi Sadoshima
Journal:  J Cardiovasc Transl Res       Date:  2010-05-01       Impact factor: 4.132

Review 8.  Role of autocrine/paracrine mechanisms in response to myocardial strain.

Authors:  Horacio E Cingolani; Irene L Ennis; Ernesto A Aiello; Néstor G Pérez
Journal:  Pflugers Arch       Date:  2011-02-08       Impact factor: 3.657

9.  Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway.

Authors:  Vinodkumar B Pillai; Nagalingam R Sundaresan; Gene Kim; Madhu Gupta; Senthilkumar B Rajamohan; Jyothish B Pillai; Sadhana Samant; P V Ravindra; Ayman Isbatan; Mahesh P Gupta
Journal:  J Biol Chem       Date:  2009-11-24       Impact factor: 5.157

10.  Lats2 is a negative regulator of myocyte size in the heart.

Authors:  Yutaka Matsui; Noritsugu Nakano; Dan Shao; Shumin Gao; Wenting Luo; Chull Hong; Peiyong Zhai; Eric Holle; Xianzhong Yu; Norikazu Yabuta; Wufan Tao; Thomas Wagner; Hiroshi Nojima; Junichi Sadoshima
Journal:  Circ Res       Date:  2008-10-16       Impact factor: 17.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.